TIDMORPH
Open Orphan PLC
12 April 2022
Open Orphan plc
("Open Orphan" or the "Company")
Presentation at World Vaccine Congress
hVIVO presents on the outcomes from the world's first COVID-19
characterisation study
Open Orphan plc (AIM: ORPH), a rapidly growing specialist
contract research organisation (CRO) and world leader in testing
infectious and respiratory disease products using human challenge
clinical trials, announces that Dr Andrew Catchpole, Chief
Scientific Officer of hVIVO , a subsidiary of Open Orphan plc, will
be delivering a presentation at the World Vaccine Congress,
Washington D.C., United States, titled 'Outcome of the world's
first SARS-CoV-2 viral challenge and its utility for vaccine
testing'.
Dr Catchpole will be presenting the results from the world's
first COVID-19 characterisation study, which was a partnership
between hVIVO, Imperial College London, the Vaccine Taskforce and
Department of Health and Social Care (DHSC), and the Royal Free
London NHS Foundation Trust. The landmark study , published in
Nature Medicine on 31 March 2022, found that a SARS-CoV-2 human
challenge is safe in healthy young adults and provided detailed
insights into the course of COVID-19 infection with potential
positive public health implications, which will also be outlined in
Dr Catchpole's presentation.
Full details of the presentation are included below:
Title Outcome of the world's first SARS-CoV-2 viral challenge
and its utility for vaccine testing
Date/Time Wednesday 20 April 2022, 09.40 am (ET)
The World Vaccine Congress will take place at the Marriott
Marquis in Washington DC between 18-21 April 2022. hVIVO will be at
booth 410 during the congress for potential partnering
discussions.
The World Vaccine Congress is the largest and most established
meeting dedicated to vaccines and has run for 21 years. In that
period, it has evolved and grown into the leading vaccines congress
globally, with hundreds of speakers and thousands of attendees from
leading global vaccines developers, academia and policymakers.
More information about the event, including attendance, can be
found here .
Yamin 'Mo' Khan, Chief Executive Officer at Open Orphan, said:
"I am delighted that Andrew will be presenting at the largest
vaccine event of the year, highlighting the pivotal role hVIVO
played in the world's first COVID-19 characterisation study ."
Interested in becoming a volunteer?
hVIVO recruits many of its volunteers for its challenge study
clinical trials through its dedicated volunteer recruitment
website, www.flucamp.com . By volunteering to take part in one of
our studies in a safe, controlled, clinical environment under
expertly supervised conditions you are playing your part to further
medical research and help increase the understanding of respiratory
illnesses.
For further information please contact:
Open Orphan plc +353 (0) 1 644 0007
Cathal Friel, Executive Chairman
Yamin 'Mo' Khan, Chief Executive
Officer
Arden Partners plc (Nominated Adviser
and Joint Broker) +44 (0) 20 7614 5900
John Llewellyn-Lloyd / Louisa Waddell
finnCap plc (Joint Broker) +44 (0) 20 7220 0500
Geoff Nash / James Thompson / Richard
Chambers
Davy (Euronext Growth Adviser and
Joint Broker) +353 (0) 1 679 6363
Anthony Farrell
Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or openorphan@walbrookpr.com
Paul McManus / Sam Allen / +44 (0)7980 541 893 / +44 (0) 7502 558
Louis Ashe-Jepson 258 /
+44 (0)7747 515 393
Notes to Editors
Open Orphan plc (London and Euronext: ORPH) is a rapidly growing
contract research company that is a world leader in testing
infectious and respiratory disease products using human challenge
clinical trials. The Company provides services to Big Pharma,
biotech, and government/public health organisations.
The Company has a leading portfolio of human challenge study
models for infectious and respiratory diseases and is developing a
number of new models, such as malaria and COVID-19, to address the
dramatic growth of the global infectious disease market. The Paris
and Breda offices have over 25 years of experience providing drug
development services such as biometry, data management, statistics
CMC, PK and medical writing to third party clients as well as
supporting the London-based challenge studies.
Open Orphan runs challenge studies in London from its
Whitechapel quarantine clinic, its state-of-the-art QMB clinic with
its highly specialised on-site virology and immunology laboratory,
and its newly opened clinic in Plumbers Row. To recruit volunteers
/ patients for its studies, the Company leverages its unique
clinical trial recruitment capacity via its FluCamp volunteer
screening facilities in London and Manchester. The newly opened
facilities have expanded the scope of the business to enable the
offering of Phase I and Phase II vaccine field trials, PK studies,
bridging studies, and patient trials as part of large international
multi-centre studies.
Building upon its many years of challenge studies and virology
research, the Company is developing an in-depth database of
infectious disease progression data. Based on the Company's Disease
in Motion(R) platform, this unique dataset includes clinical,
immunological, virological, and digital (wearable) biomarkers.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRASFIFSEEESEDL
(END) Dow Jones Newswires
April 12, 2022 07:00 ET (11:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2023 to Apr 2024
